TGFB1 and non-small cell lung carcinoma: We show that the acquisition of a mesenchymal phenotype by ALK-rearranged NSCLC cells following chronic exposure to crizotinib or to TGFβ stimulation increases resistance to the second-generation ALK–TKI brigatinib and promotes full refractoriness to the third-generation ALK–TKI lorlatinib.